Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

S. Cascinu, R. Labianca, S. Barni, L. Frontini, M. Ligi, E. Del Ferro, R. R. Silva, G. Pancera, M. A. Pessi, P. Giordani, R. Agostinelli, V. Catalano, M. B L Rocchi, G. Ghiandoni, G. Luporini, G. Catalano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalGI Cancer
Volume3
Issue number1
Publication statusPublished - 1999

Fingerprint

Stomach Neoplasms
Gastrointestinal Tract
Drug Therapy
Levoleucovorin
Weight Loss
Pharmaceutical Preparations
Neoplasms
Epirubicin
Cardia
Stereoisomerism
Granulocyte Colony-Stimulating Factor
Aspartate Aminotransferases
Alanine Transaminase
Fluorouracil
Cisplatin
Statistical Factor Analysis
Disease-Free Survival
Glutathione
Alkaline Phosphatase
Albumins

Keywords

  • Gastric cancer
  • Prognostic factor to chemotherapy
  • Toxicity

ASJC Scopus subject areas

  • Gastroenterology
  • Oncology

Cite this

Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). / Cascinu, S.; Labianca, R.; Barni, S.; Frontini, L.; Ligi, M.; Del Ferro, E.; Silva, R. R.; Pancera, G.; Pessi, M. A.; Giordani, P.; Agostinelli, R.; Catalano, V.; Rocchi, M. B L; Ghiandoni, G.; Luporini, G.; Catalano, G.

In: GI Cancer, Vol. 3, No. 1, 1999, p. 79-83.

Research output: Contribution to journalArticle

Cascinu, S, Labianca, R, Barni, S, Frontini, L, Ligi, M, Del Ferro, E, Silva, RR, Pancera, G, Pessi, MA, Giordani, P, Agostinelli, R, Catalano, V, Rocchi, MBL, Ghiandoni, G, Luporini, G & Catalano, G 1999, 'Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)', GI Cancer, vol. 3, no. 1, pp. 79-83.
Cascinu, S. ; Labianca, R. ; Barni, S. ; Frontini, L. ; Ligi, M. ; Del Ferro, E. ; Silva, R. R. ; Pancera, G. ; Pessi, M. A. ; Giordani, P. ; Agostinelli, R. ; Catalano, V. ; Rocchi, M. B L ; Ghiandoni, G. ; Luporini, G. ; Catalano, G. / Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). In: GI Cancer. 1999 ; Vol. 3, No. 1. pp. 79-83.
@article{e7a30f8ed8074cb48cd80a28f03bc329,
title = "Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)",
abstract = "We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10{\%}, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100{\%} versus <79{\%}), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.",
keywords = "Gastric cancer, Prognostic factor to chemotherapy, Toxicity",
author = "S. Cascinu and R. Labianca and S. Barni and L. Frontini and M. Ligi and {Del Ferro}, E. and Silva, {R. R.} and G. Pancera and Pessi, {M. A.} and P. Giordani and R. Agostinelli and V. Catalano and Rocchi, {M. B L} and G. Ghiandoni and G. Luporini and G. Catalano",
year = "1999",
language = "English",
volume = "3",
pages = "79--83",
journal = "GI Cancer",
issn = "1064-9700",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

AU - Cascinu, S.

AU - Labianca, R.

AU - Barni, S.

AU - Frontini, L.

AU - Ligi, M.

AU - Del Ferro, E.

AU - Silva, R. R.

AU - Pancera, G.

AU - Pessi, M. A.

AU - Giordani, P.

AU - Agostinelli, R.

AU - Catalano, V.

AU - Rocchi, M. B L

AU - Ghiandoni, G.

AU - Luporini, G.

AU - Catalano, G.

PY - 1999

Y1 - 1999

N2 - We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.

AB - We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.

KW - Gastric cancer

KW - Prognostic factor to chemotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0033025555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033025555&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 79

EP - 83

JO - GI Cancer

JF - GI Cancer

SN - 1064-9700

IS - 1

ER -